Granted Patent
B2
US 12,427,152 · App. 16/317,766 · Granted Sep 30, 2025
HDAC inhibitors for use with NK cell based therapies
A61K31/522A61K9/0053A61K31/4709A61K31/506A61K38/15A61K38/177A61K38/1774A61K39/3955A61K39/39558A61K40/11A61K40/31A61K40/46A61K45/06A61P31/22A61P35/00A61P35/04C12N9/80A61K2039/505A61K2239/31A61K2239/38A61K2239/48A61K2239/51
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.
Claims (9)
1. A method for treating an androgen-independent prostate cancer in an individual afflicted with the androgen-independent prostate cancer, the method comprising administering to the individual afflicted with the androgen-independent prostate cancer:
a) CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide); and
b) a primary human NK cell.
2. The method of claim 1 , wherein CHR-3996 is administered orally.
3. The method of claim 1 , wherein CHR-3996 is administered at a dose of less than 40 mg per day.
4. The method of claim 1 , wherein CHR-3996 is administered at a dose of less than 20 mg per day.
5. The method of claim 1 , wherein CHR-3996 is administered prior to the administration of the primary human NK cell.
6. The method of claim 1 , wherein CHR-3996 is administered during the administration of the primary human NK cell.
7. The method of claim 1 , wherein CHR-3996 is administered after the administration of the primary human NK cell.
Assignments (3)
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 2, 2019
From: SOON-SHIONG, PATRICK
To: NANTKWEST, INC.
Reel/Frame 049067/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 2, 2019
From: WOODY, JAMES N.
To: VIRACTA THERAPEUTICS, INC.
Reel/Frame 049078/0130 →
Continuity (2)
Provisional Application
62362959
· Jul 15, 2016
References Cited (400)
US 3471513A
· Leland
· 1969
[cited by applicant]
US 3904612A
· Nagasawa et al.
· 1975
[cited by applicant]
US 4008323A
· Cousse et al.
· 1977
[cited by applicant]
US 4011336A
· Amann et al.
· 1977
[cited by applicant]
US 4026895A
· Tanaka et al.
· 1977
[cited by applicant]
US 4026896A
· Harita et al.
· 1977
[cited by applicant]
US 4031243A
· Aparicio et al.
· 1977
[cited by applicant]
US 4058558A
· Cousse et al.
· 1977
[cited by applicant]
US 4131617A
· Esanu
· 1978
[cited by applicant]
US 4176193A
· Esanu
· 1979
[cited by applicant]
US 4234599A
· Van Scott et al.
· 1980
[cited by applicant]
US 4613616A
· Winston et al.
· 1986
[cited by applicant]
US 4671901A
· Green
· 1987
[cited by applicant]
US 4699926A
· Abraham et al.
· 1987
[cited by applicant]
US 4704402A
· Abraham et al.
· 1987
[cited by applicant]
US 4723958A
· Pope et al.
· 1988
[cited by applicant]
US 4731381A
· Abraham et al.
· 1988
[cited by applicant]
US 4732914A
· Morton, Jr.
· 1988
[cited by applicant]
US 4735967A
· Neesby
· 1988
[cited by applicant]
US 4747825A
· Linkie et al.
· 1988
[cited by applicant]
US 4751244A
· Abraham et al.
· 1988
[cited by applicant]
US 4766116A
· Tatsuoka et al.
· 1988
[cited by applicant]
US 4820711A
· Pearlman
· 1989
[cited by applicant]
US 4822821A
· Perrine
· 1989
[cited by applicant]
US 4849426A
· Pearlman
· 1989
[cited by applicant]
US 4851229A
· Magruder et al.
· 1989
[cited by applicant]
US 4853388A
· Pearlman
· 1989
[cited by applicant]
US 4880624A
· Metcalf et al.
· 1989
[cited by applicant]
US 4894364A
· Greer
· 1990
[cited by applicant]
US 4925873A
· Friedhoff et al.
· 1990
[cited by applicant]
US 4948592A
· Ayer et al.
· 1990
[cited by applicant]
US 4952560A
· Kigasawa et al.
· 1990
[cited by applicant]
US 4958592A
· Anthony et al.
· 1990
[cited by applicant]
US 4965251A
· Stamatoyannopoulos
· 1990
[cited by applicant]
US 4968340A
· Kaku et al.
· 1990
[cited by applicant]
US 4997815A
· Perrine et al.
· 1991
[cited by applicant]
US 5023251A
· Sattler et al.
· 1991
[cited by applicant]
US 5025029A
· Perrine
· 1991
[cited by applicant]
US 5032507A
· Yu et al.
· 1991
[cited by applicant]
US 5039703A
· Breuer
· 1991
[cited by applicant]
US 5081124A
· Hughes
· 1992
[cited by applicant]
US 5100647A
· Agus et al.
· 1992
[cited by applicant]
US 5137734A
· Spiegelman et al.
· 1992
[cited by applicant]
US 5139563A
· Astles et al.
· 1992
[cited by applicant]
US 5185436A
· Villa et al.
· 1993
[cited by applicant]
US 5199942A
· Gillis
· 1993
[cited by applicant]
US 5208333A
· Paul et al.
· 1993
[cited by applicant]
US 5216004A
· Perrine
· 1993
[cited by applicant]
US 5258367A
· Bazer et al.
· 1993
[cited by applicant]
US 5270458A
· Lemischka
· 1993
[cited by applicant]
US 5366996A
· Elford et al.
· 1994
[cited by applicant]
US 5378716A
· Hamanaka et al.
· 1995
[cited by applicant]
US 5403590A
· Forse
· 1995
[cited by applicant]
US 5403867A
· Okumura et al.
· 1995
[cited by applicant]
US 5468731A
· Matsuo et al.
· 1995
[cited by applicant]
US 5635532A
· Samid
· 1997
[cited by applicant]
US 5654333A
· Samid
· 1997
[cited by applicant]
US 5661179A
· Samid
· 1997
[cited by applicant]
US 5674898A
· Cheng et al.
· 1997
[cited by applicant]
US 5674912A
· Martin
· 1997
[cited by applicant]
US 5679707A
· Okumura et al.
· 1997
[cited by applicant]
US 5710178A
· Samid
· 1998
[cited by applicant]
US 5750571A
· Cheng et al.
· 1998
[cited by applicant]
US 5827642A
· Riddell et al.
· 1998
[cited by applicant]
US 5843994A
· Samid
· 1998
[cited by applicant]
US 5858365A
· Faller
· 1999
[cited by applicant]
US 5932545A
· Henkin et al.
· 1999
[cited by applicant]
US 5939456A
· Perrine
· 1999
[cited by applicant]
US 5945407A
· Bemis et al.
· 1999
[cited by applicant]
US 6011000A
· Perrine et al.
· 2000
[cited by applicant]
US 6030961A
· Nudelman et al.
· 2000
[cited by applicant]
US 6043389A
· Nudelman et al.
· 2000
[cited by applicant]
US 6197743B1
· Faller
· 2001
[cited by applicant]
US 6231880B1
· Perrine
· 2001
[cited by applicant]
US 6284240B1
· Seed et al.
· 2001
[cited by applicant]
US 6316257B1
· Flyer et al.
· 2001
[cited by applicant]
US 6399054B1
· Casorati et al.
· 2002
[cited by applicant]
US 6403647B1
· Perrine
· 2002
[cited by applicant]
US 6451334B2
· Perrine
· 2002
[cited by applicant]
US 6677302B2
· Faller
· 2004
[cited by applicant]
US 7618817B2
· Campbell
· 2009
[cited by applicant]
US 7745140B2
· June et al.
· 2010
[cited by applicant]
US 8313943B2
· Campbell
· 2012
[cited by applicant]
US 8383099B2
· Dudley et al.
· 2013
[cited by applicant]
US 20010009922A1
· Faller
· 2001
[cited by applicant]
US 20010027215A1
· Perrine
· 2001
[cited by applicant]
US 20030018069A1
· Faller et al.
· 2003
[cited by applicant]
US 20030134341A1
· Gruenberg
· 2003
[cited by applicant]
US 20040241162A1
· Berenson et al.
· 2004
[cited by applicant]
US 20060074046A1
· Redkar et al.
· 2006
[cited by applicant]
US 20080015190A1
· Chakravarty et al.
· 2008
[cited by applicant]
US 20080057086A1
· Etter
· 2008
[cited by applicant]
US 20080075692A1
· Perrine
· 2008
[cited by applicant]
US 20080207590A1
· Deziel et al.
· 2008
[cited by applicant]
US 20090082444A1
· Perrine et al.
· 2009
[cited by applicant]
US 20090130134A1
· Pancre et al.
· 2009
[cited by applicant]
US 20090131367A1
· Gore et al.
· 2009
[cited by applicant]
US 20090137567A1
· Perrine et al.
· 2009
[cited by applicant]
US 20090298924A1
· Davidson et al.
· 2009
[cited by applicant]
US 20100010010A1
· Davidson et al.
· 2010
[cited by applicant]
US 20100152155A1
· Moffat et al.
· 2010
[cited by applicant]
US 20100280113A1
· Faller et al.
· 2010
[cited by applicant]
US 20110086869A1
· Perrine et al.
· 2011
[cited by applicant]
US 20110245154A1
· Berenson et al.
· 2011
[cited by applicant]
US 20110251149A1
· Perrine et al.
· 2011
[cited by applicant]
US 20130331313A1
· Berenson et al.
· 2013
[cited by applicant]
US 20150099012A1
· Mahmoudi
· 2015
[cited by applicant]
US 20150210772A1
· Kim
· 2015
[cited by applicant]
US 20160113929A1
· Berenson et al.
· 2016
[cited by applicant]
US 20170021002A1
· Wagner
· 2017
[cited by examiner]
US 20170042898A1
· Berenson
· 2017
[cited by applicant]
US 20180185345A1
· Faller
· 2018
[cited by applicant]
US 20190216818A1
· Woody
· 2019
[cited by applicant]
US 20190247481A1
· Soon-Shiong
· 2019
[cited by examiner]
US 20200270574A1
· Soon-Shiong
· 2020
[cited by examiner]
US 20200368280A1
· Warren et al.
· 2020
[cited by applicant]
US 20210213041A1
· Ting et al.
· 2021
[cited by applicant]
US 20230149413A1
· Woody
· 2023
[cited by applicant]
CA 1209037A1
· 1986
[cited by applicant]
CA 2173976A1
· 1995
[cited by applicant]
CA 3002755A1
· 2017
[cited by applicant]
CN 102391359A
· 2012
[cited by applicant]
CN 102793693A
· 2012
[cited by applicant]
CN 103232474A
· 2013
[cited by applicant]
CN 104083763A
· 2014
[cited by applicant]
CN 105055386A
· 2015
[cited by applicant]
CN 105647946A
· 2016
[cited by applicant]
CN 108347929A
· 2018
[cited by applicant]
EP 2683371A1
· 2014
[cited by applicant]
GB 2126082A
· 1984
[cited by applicant]
JP S5089335A
· 1975
[cited by applicant]
JP S61180740A
· 1986
[cited by applicant]
JP 6208667B2
· 2017
[cited by applicant]
RU 2555474C1
· 2015
[cited by applicant]
WO WO9307866A2
· 1993
[cited by applicant]
WO WO9307866A3
· 1993
[cited by applicant]
WO WO9511699A1
· 1995
[cited by applicant]
WO WO9627369A2
· 1996
[cited by applicant]
WO WO9627369A3
· 1996
[cited by applicant]
WO WO9704761A1
· 1997
[cited by applicant]
WO WO9804290A2
· 1998
[cited by applicant]
WO WO9804290A3
· 1998
[cited by applicant]
WO WO2006121168A1
· 2006
[cited by applicant]
WO WO2008097654A1
· 2008
[cited by applicant]
WO WO2012120262A1
· 2012
[cited by applicant]
WO WO2013033656A1
· 2013
[cited by applicant]
WO WO2013086379A2
· 2013
[cited by applicant]
WO WO2013110280A1
· 2013
[cited by applicant]
WO WO2013149026A2
· 2013
[cited by applicant]
WO WO2013181584A2
· 2013
[cited by applicant]
WO WO2014144791A2
· 2014
[cited by applicant]
WO WO2015010096A1
· 2015
[cited by applicant]
WO WO2015160986A2
· 2015
[cited by applicant]
WO WO2016077734A2
· 2016
[cited by applicant]
WO WO2016109668A1
· 2016
[cited by applicant]
WO WO2016153839A1
· 2016
[cited by applicant]
WO WO2016205695A1
· 2016
[cited by applicant]
WO WO2017041043A1
· 2017
[cited by applicant]
WO WO2017053823A1
· 2017
[cited by applicant]
WO WO2017100709A1
· 2017
[cited by applicant]
WO WO2017120204A2
· 2017
[cited by applicant]
WO WO2017197140A1
· 2017
[cited by applicant]
WO WO2017202949A1
· 2017
[cited by applicant]
WO WO2018013962A1
· 2018
[cited by applicant]
WO WO2018013975A1
· 2018
[cited by applicant]
WO WO2019072220A1
· 2019
[cited by applicant]
WO WO2019140296A1
· 2019
[cited by applicant]
WO WO2023003972A1
· 2023
[cited by applicant]
Rezvani et al. (Mol. Ther. Aug. 2, 2017; 25 (8): 1769-1781).
[cited by examiner]
Hermanson et al. (Front. Immunol. Apr. 28, 2015; 6: 195; pp. 1-6).
[cited by examiner]
Liu et al. (Clin. Cancer Res. 2013; 19 (8): 2132-43).
[cited by examiner]
Kim et al. (Proc. Natl. Acad. Sci. USA. Aug. 12, 2014; 111 (32):11774-9).
[cited by examiner]
Moffat et al. (J. Med. Chem. Dec. 23, 2010; 53 (24): 8663-78).
[cited by examiner]
Deeks (Drugs. Jul. 2014; 74 (11): 1233-9).
[cited by examiner]
Bora-Singhal et al. (Sci. Rep. Mar. 13, 2020; 10 (1): 4722; pp. 1-20).
[cited by examiner]
Jochems et al. (Oncotarget. Dec. 27, 2016; 7 (52): 86359-86373).
[cited by examiner]
Héninger et al. (Front. Immunol. Feb. 4, 2015; 6: 29; pp. 1-14).
[cited by examiner]
Rajan et al. (Sci. Rep. 2018; 8: 13072; pp. 1-11).
[cited by examiner]
Klingermann et al. (Front. Immunol. Apr. 28, 2015; 6: 195; pp. 1-7).
[cited by examiner]
Ingram et al. (Proc. Natl. Acad. Sci. USA. Apr. 10, 2018; 115 (15): 3912-3917).
[cited by examiner]
Chin et al. (Chang Gung Med J. Jan.-Feb. 2008; 31 (1): 1-15).
[cited by examiner]
Jiang et al. (J. Biol. Chem. Feb. 11, 2005; 280 (6): 4656-4662).
[cited by examiner]
Riemer et al. (Mol. Immunol. 2005; 42: 1121-1124).
[cited by examiner]
West et al. (J. Clin. Invest. Jan. 2, 2014; 124 (1): 30-9).
[cited by examiner]
Taylor et al. (Cancer Immunol. Immunother. Jul. 2009; 58 (7): 997-1006).
[cited by examiner]
Klingemann et al. (Front. Immunol. Mar. 14, 2016; 7: 91; pp. 1-7).
[cited by examiner]
Jochems et al. (Int. J. Cancer. Aug. 1, 2017; 141 (3): 583-593).
[cited by examiner]
Fujii et al. (J. Neurosurg. May 2018; 128 (5): 1419-1427).
[cited by examiner]
Hsieh et al. (J. Immunol. Methods. Feb. 2017; 441: 56-66).
[cited by examiner]
Kaushik et al. (Ther. Adv. Urol. Dec. 2015; 7 (6): 388-95).
[cited by examiner]
Banerji et al. (Clin. Cancer Res. May 1, 2012; 18 (9): 2687-94).
[cited by examiner]
Halkidou et al. (Prostate. May 1, 2004; 59 (2): 177-89).
[cited by examiner]
Welsbie et al. (Cancer Res. Feb. 1, 2009; 69 (3): 958-66).
[cited by examiner]
Davies et al. (Cytotherapy. Nov. 2014; 16 (11): 1453-66; author manuscript; pp. 1-23).
[cited by examiner]
Cheng et al. (Cell. Mol. Immunol. May 2013; 10 (3): 230-52).
[cited by examiner]
Dahlberg et al. (Front. Immunol. 2015; 6: 605; pp. 1-19).
[cited by examiner]
Alici et al. (Chapter 10: Retroviral Gene Transfer into Primary Human Natural Killer Cells. In: Baum, C. (eds.) Genetic Modification of Hematopoietic Stem Cells. Methods in Molecular Biology™, 2009; Humana Press; 506: 1…
[cited by examiner]
Abbott, et al. Quantitative structure-anticonvulsant activity relationships of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology. Mar. 1988;27(3):287-94.
[cited by applicant]
Almstedt et al., The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research. 34(7):899-905 (2010).
[cited by applicant]
Antoni, et al. NF-.kappa. B-Dependent and -Independent Pathways of HIV Activation in a Chronically Infected T Cell Line. Virology. 1994;202:684-694.
[cited by applicant]
Archin, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. Feb. 23, 2010;5(2):e9390 (p. 1-4).
[cited by applicant]
Archin, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. Feb. 2009;25(2):207-12.
[cited by applicant]
Archin, et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. Sep. 10, 2009;23(14):1799-806.
[cited by applicant]
Archin, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. Jun. 19, 2008;22(10):1131-5.
[cited by applicant]
Armstrong, et al. Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease. Leukemia. 6(9):869-874.
[cited by applicant]
Arvey et al., An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host & Microbe. 12(2):233-245 (2012).
[cited by applicant]
Barker, et al. The actions of cyclic AMP, its butyryl derivatives and Na butyrate on the proliferation of malignant trophoblast cells in vitro, Br. J. Cancer. 1977;35:314-321.
[cited by applicant]
Bingham. Patty's Toxicology. John Wiley and Sons, Incorporated. Jan. 1, 2001;5:707-711.
[cited by applicant]
Bloch. Induced cell differentiation in cancer therapy. Cancer Treatment Reports. 1984;68:199-205.
[cited by applicant]
Bohan, et al. Mutational analysis of sodium butyrate inducible elements in the human immunodeficiency virus type 1 long terminal repeat. Virology. 1989;172:573-583.
[cited by applicant]
Bohan, et al. Sodium butyrate activates human immunodeficiency virus long terminal repeat—directed expression. Biochem and Biophys. Res. Comm. 1987;148(3):899-905.
[cited by applicant]
Bonnet et al., Detection of Epstein-Barr virus in invasive breast cancers. J Nat Cancer Inst. 91(16):1376-1381 (1999).
[cited by applicant]
Bourgeade, et al. Effect of sodium butyrate on the antiviral and anticellular action of interferon in normal and MSV-transformed cells. Int J Cancer. Sep. 15, 1979;24(3):314-8.
[cited by applicant]
Bourgeade, et al. Enhancement of interferon anti-tumor action by sodium butyrate. Cancer Res. 1979;39:4720-4723.
[cited by applicant]
Bridle et al,. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Molecular Therapy. 21(4):887-894 (2013) . . . .
[cited by applicant]
Briz et al., Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia. British Journal of Haematology. 98(2):485-487 (1997).
[cited by applicant]
Brooks, et al. Epstein-Barr virus and lymphomas. Cancer Surv. 1999;33:99-123.
[cited by applicant]
Burkitt, A sarcoma involving the jaws in African children. The British Journal of Surgery. 46(127):218-223 (1958).
[cited by applicant]
Callery, et al. Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans. Cancer Res. 1986;46:4900-4903.
[cited by applicant]
Canceill, et al. Stereochimstry of the reduction of b-keto esters, p-keto amides, and b-keto nitriles by hydrides. Bull. Soc. Chim. 1970 Fr. 6:2180-2187. (Abstract only).
[cited by applicant]
Caruso, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A. Aug. 1, 1993;90(15):7024-8.
[cited by applicant]
Choi et al., Activation of CMV promoter-controlled glycosyltransferase and beta-galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconjugate Journal. 22(1-2):63-69 (2005) . . . .
[cited by applicant]
Chu, et al. In situ detection of Epstein-Barr virus in breast cancer. Cancer Lett. 1998;124:53-57.
[cited by applicant]
Chung, et al. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. Clin Cancer Res. Apr. 2000;6(4):14…
[cited by applicant]
Coates, et al. Persistence of Epstein-Barr virus in Reed-Sternberg cells throughout the course of Hodgkin's disease. J Pathol. 1991;164:291-291.
[cited by applicant]
Colombo. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. Journal of Hepatology. 1999;31:(1):25-30. Suppl.
[cited by applicant]
Coral et al., Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. Journal of Cellular Physiology. 207(1):58-66 (2006).
[cited by applicant]
Countryman et al., Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. …
[cited by applicant]
Curtis, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood. 1999;94:2208-2216.
[cited by applicant]
Cycon et al., Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 140(2):259-272 (2013) . . . .
[cited by applicant]
Daniel. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clinica Chimica Acta. 1989;181:255-264.
[cited by applicant]
Dantchev,et al. Behavior of certain pyrimidine compounds of fumeric acid, and of malic acid with regard to the protection of red blood cells of the rabbit intoxicated with phenylhydrazine. Comportement de certain compos…
[cited by applicant]
De Bruin, et al. Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein I positively and clinical course. Histopathology. 1993;23:509-509.
[cited by applicant]
De Bruin, et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood. 1994;83(10):1612-1612.
[cited by applicant]
De Smet et al., DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Molecular and Cellular Biology. 19(11):7327-7335 (1999).
[cited by applicant]
De Smet et al., The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proceedings of the National Academy of Sciences of the United States of America. 93(14):7149-7153 (1996).
[cited by applicant]
Dimaio, et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. Aug. 1994;116(2):205-13.
[cited by applicant]
Dokmanovic, et al. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. Oct. 2007;5(10):981-9.
[cited by applicant]
Egorin, et al. Phase 1 clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer. Res. 1987;47:617-623.
[cited by applicant]
Elaut, et al. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des. 2007;13(25):2584-620.
[cited by applicant]
EP 10184726 Search Report mailed Jan. 20, 2011.
[cited by applicant]
European office action dated Aug. 11, 2010 for Application No. 6021311.3.
[cited by applicant]
Faller, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr Virus (EBV) associated lymphona. Am. Soc. of Hematology [Blood]. 1995;86(10)(1):342a.
[cited by applicant]
Faller, et al. Arginine Butyrate-induced susceptibility to ganciclovir in Epstein-Barr virus (EBV)-associated lymphomas. Proceedings of the American Association for Cancer Research. 1996;37:411-412.
[cited by applicant]
Faller, et al. Phase I/II trial of arginne butyrate to induce viral TK gene expression in Epstein-Barr Virus (EBV)-associated lymphomas. Proc. Am. Assn. for Cancer Research. Mar. 2000;41:544. (Abstract only).
[cited by applicant]
Feng, et al. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.Cancer Res. Sep. 1, 2006;66(17):8762-9.
[cited by applicant]
Flyer, et al. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. The Journal of Immunology. Oct. 1985;135(4):2287-92.
[cited by applicant]
Foss, et al. Biomodulatory effects of butyric acid derivatives on leukemia and lymphoma cells. Blood. 1993; 82/10 Suppl. 1:564A. (1993) The American Society of Hematology, 35th Annual Meeting, Dec. 3-7, Abstract only.
[cited by applicant]
Ghosh, et al. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis. Jan.-Feb. 2007;38(1):57-65. Epub Dec. 11,…
[cited by applicant]
Gilbert, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. Aug. 2001;7(8):2292-300.
[cited by applicant]
Glaser, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382.
[cited by applicant]
Glaser, K. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. Sep. 1, 2007;74(5):659-71. Epub Apr. 7, 2007.
[cited by applicant]
Golub, et al. Induction of dormant HIV-1 by sodium butyrate: involvement of the TATA box in the activation of the HIV-1 promoter. AIDS. 1991;5(6):663-668.
[cited by applicant]
Gradoville, et al. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol. Jun. 2002;76(11):5612-26.
[cited by applicant]
Gredmark, et al. Active cytomegalovirus replication in patients with coronary disease. Scand Cardiovasc J. Aug. 2007;41(4):230-4.
[cited by applicant]
Greenspan, et al. Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. N Engl J Med. 1985;313:1564-1564.
[cited by applicant]
Gross, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation. Risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251-258.
[cited by applicant]
Grossi, et al., Effects of monosaccharide esters of butyric acid on the synthesis of hemoglobin T chain and erythroleukemis cell line, Abstract of ASH Annual Meeting, Seattle, WA, Dec. 1-5, 1995.
[cited by applicant]
Grufferman, et al. Hodgkin's disease in siblings. N Engl J Med. 1977;296:248-250.
[cited by applicant]
Guilbaud, et al. Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. Journal of Cellular Physiology. 1990;145:162-172.
[cited by applicant]
Gum, et al. Effects of sodium butyrate on human colonic adenocarcinoma cells. The Journal of Biological Chemistry. Jan. 25, 1987;262(3):1092-1097.
[cited by applicant]
Hahn, et al. Therapeutic outcome of Epstein-Barr virus positive T/NK cell lymphoma in the upper aerodigestive tract. Yonsei Med J. 2002;43:175-182.
[cited by applicant]
Hanto, et al. Epstein-Barr virus-induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg. 1983;198:356-369.
[cited by applicant]
Harabuchi, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128-128.
[cited by applicant]
Harig, et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N. Engl. J. Med. 1989;320(1):23-28.
[cited by applicant]
Henle et al., Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA. 59(1):94-101 (1968) . . . .
[cited by applicant]
Henle, et al. Epstein-Barr virus and human malignancies. Cancer. Oct. 1974;34(4 Suppl):suppl:1368-74.
[cited by applicant]
Henry, D.H. Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?. The Oncologist. Aug. 1998;3(4): 275-8.
[cited by applicant]
Herbst et al., Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA. 88(11):476-4770 (1991).
[cited by applicant]
Ho, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas. Hematol Oncol. 1990;8:271-271.
[cited by applicant]
Hoessly, et al. Factors responsible for variable reported lineages of HL-60 cells induced to mature with butyric acid. Cancer Research. Jul. 1, 1989;49:3594-97.
[cited by applicant]
Hoey, et al. Molecular cloning and functional analysis of
[cited by applicant]
Hsu, et al. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34:27-53.
[cited by applicant]
Huber, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. Oct. 1, 1993;53(19):4619-26.
[cited by applicant]
Huber, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells expre…
[cited by applicant]
International Application No. PCT/US17/42199 International Search Report and Written Opinion Mailed Oct. 6, 2017.
[cited by applicant]
International Application No. PCT/US2016/038148 International Preliminary Report on Patentability Mailed Dec. 28, 2017.
[cited by applicant]
Jiwa, et al. Epstein-Barr virus DNA in Reed-Sternberg cells of Hodgkin's disease is frequently associated with CR2 (Ebv receptor) expression. Histopathology. 1992;21:51-51.
[cited by applicant]
Johansson, et al. Epstein-Barr Virus (EBV)-associated antibody pattern in malignant lymphoma and leukemia. 1. Hodgkin's disease. Int J Cancer. 1970;5:450-450.
[cited by applicant]
Jones, et al. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Int J Lab Hematol. Feb. 2010;32(1 Pt 1):e169-74. Epub Jan. 12, …
[cited by applicant]
Jones, et al. T-cell lymphomas containing Epstein-Barr virus DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318(12):733-733.
[cited by applicant]
Kawa. Epstein-Barr virus-associated disease in humans. Int J Hematol. 2000;71:108-117.
[cited by applicant]
Keedy, et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol. May 2009;83(10):4749-56.
[cited by applicant]
Kim et al., Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proceedings of the National Academy of Sciences of the United States of America. 111(3…
[cited by applicant]
Kleer, et al. Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts. Modern Pathol. 2002;15(7):759-764.
[cited by applicant]
Korbjuhn et al., Frequent latent Epstein-Barr virus infection of neoplastic T cells and bystander B cells in human immunodeficiency virus-negative European peripheral pleomorphic T-cell lymphomas. Blood. 82(1):217-223 (…
[cited by applicant]
Krantis, et al. Augmentation of cysteamine-induced ulceration of rat duodenum by systemically administered g-Aminobutyric Acid (GABA). Digestive Diseases and Sciences. Aug. 1989;34(8m):1211-1216.
[cited by applicant]
Kroesen et al., HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 5(16):6558-6572 (2014) . . . .
[cited by applicant]
Kwong, et al. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol. 1997;15:71-79.
[cited by applicant]
Lee, et al. Essential role of PKCdelta in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells. J Gen Virol. Apr. 2008;89(Pt 4):878-83.
[cited by applicant]
Lee, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med. 1995;332:19-25.
[cited by applicant]
Leoncini, et al. Epstein-Barr virus and gastric cancer: data and unanswered questions. Int J Cancer. 1993;53:898-901.
[cited by applicant]
Magrath, et al. Breast cancer: a new Epstein-Barr virus-associated disease? J Nat Cancer Inst. 1999;91:1349-1350.
[cited by applicant]
Maia, et al. Chronic, active Epstein-Barr virus infection. Curr Opin Hematol. 2000;7:59-63.
[cited by applicant]
Matalon, et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. Journal of Acq…
[cited by applicant]
Maziarz, et al. The regulation of exogenous and endogenous class I MHC genes in a human tumor cell line, K562. Molecular Immunology. 1990;27:135-142.
[cited by applicant]
McClain, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med. 1995;332:12-18.
[cited by applicant]
Meijer, et al. Epstein-Barr virus and human T-cell lymphomas. Seminars in Cancer Biology. Aug. 1996;7(4):191-196.
[cited by applicant]
Miller, et al. Antibodies to butyrate-inducible antigens of Kaposi's Sarcoma-associated herpesvirus to patient with HIV-1 infection. The New England J. of Med. 1996;334(20):1292-1297.
[cited by applicant]
Miller, et al. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol. 1987;23(9):1283-1287.
[cited by applicant]
Moffat, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.J Med Chem. De…
[cited by applicant]
Mottamal et al., Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 20(3):3898-3941 (2015) . . . .
[cited by applicant]
Mueller, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989;320:689-689.
[cited by applicant]
Murata and Tsurumi, Switching of EBV cycles between latent and lytic states. Reviews in Medical Virology. 24(3):142-153 (2014) . . . .
[cited by applicant]
Muro, K. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology, S1470-2045(26)00175-3 (May 3, 2016).
[cited by applicant]
Nguyen et al., Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Science. 105(39): 1498…
[cited by applicant]
Niedobitek et al., Epstein-Barr virus gene expression in Hodgkin's disease. Blood. 78(6):1628-1630 (1991).
[cited by applicant]
Niedobitek. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Annals of Oncology. 7:S11-S17 (1996) . . . .
[cited by applicant]
Nudelman, et al. Novel anticancer prodrugs of butyric acid. 2. J Med Chem. Feb. 21, 1992;35(4):687-94.
[cited by applicant]
Osato, et al. Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol. 1996;7:175-182.
[cited by applicant]
Pagano. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians. 1999;111:573-580.
[cited by applicant]
Pauken et al., Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 354(6316):1160-1165 (2016).
[cited by applicant]
Pender et al., Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clinical & Translational Immunology. 6(1):e126 (2017). doi: 10.1038/cti.2016.87. eCollection Jan. 2017.
[cited by applicant]
Perez, et al. Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency. Curr HIV Res. Sep. 1, 2010;8(6):418-29.
[cited by applicant]
Perrine, et al. A phase 1,2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6):2571-2578.
[cited by applicant]
Perrine, et al. An Interleukin 2/Sodium Butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gasteroenterology. 1994;107:1697-1708.
[cited by applicant]
Pouillart, et al. Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon. Int. J. Cancer. 1992;51:596-601.
[cited by applicant]
Reynolds. The Extra Pharmacopoeia, 29th edition, 1989:1359.
[cited by applicant]
Rickinson, et al. Epstein-Barr virus. In Fields Virology, vol. 2, 3rd Ed., B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia. 1996:2397-2446.
[cited by applicant]
Rius, et al. The induction of vimentin gene expression by sodium butyrate in human promonocytic leukemia U937 cells. Experimental Cell Research. 1990;188:129-134.
[cited by applicant]
Rotili, et al. Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies. Curr Top Med Chem. 2009;9(3):272-91.
[cited by applicant]
Rowe, et al. Colonic short-chain fatty acids: fuel from the lumen? Gastroenterology. Jul. 1992;103(1):336-8.
[cited by applicant]
Roychowdhury, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. Oct. 6, 2004;96(19):1447-57.
[cited by applicant]
Sachs. Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Research. 1987;47:1981-1986.
[cited by applicant]
Sadaie, et al. Induction of developmentally programmed cell death and activation of HIV by sodium butyrate. Virology. 1994;202:513-518.
[cited by applicant]
Saito, et al. A synthetic inhibitor of histone deacetuylase, MS-27-275. Proceedings of the National Academy of Sciences USA, Apr. 1999, vol. 96, pp. 4592-4597.
[cited by applicant]
Shen et al., Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 7(1):e30815 (2012).
[cited by applicant]
Shen et al., Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. 8(3):415-428 (2016).
[cited by applicant]
Shibata, et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;91:2101-2109.
[cited by applicant]
Slamon, et al. Expression of cellular oncogenes in human malignancies. Science. 1984;224:256-262.
[cited by applicant]
Speck, et al. Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact. J Nat Cancer Inst. 2000;92:1849-1851.
[cited by applicant]
Srivastava et al., Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 10(3):237-246 (2015) . . . .
[cited by applicant]
Su, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysis. Blood. 1991;77:799-808.
[cited by applicant]
Swinnen. Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol. 1999;26:21-25.
[cited by applicant]
Tang, et al. Memory of butyrate induction by the moloney murine sarcoma virus enhancer-promoter element. Biochem and Biophys Res. Comm. 1992;189(1):141-147.
[cited by applicant]
Toussirot, et al. Epstein-Barr virus in autoimmune diseases. Best Practice & Research Clinical Rheumatology. 2008;22(5):883-896.
[cited by applicant]
Tsai, et al. Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. J Virol. Mar. 2011;85(5):2373-85. Epub Dec. 15, 2010.
[cited by applicant]
Watson, et al. Butyrate acid in the treatment of cancer. The Lancet. 1933:746-748.
[cited by applicant]
Weiss, et al. Detection of Epstein-Barr virus in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320(8):502-502.
[cited by applicant]
Weiss, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129:86-86.
[cited by applicant]
Williams, et al. Identification of a Ligand for the o-kit Proto-Oncogene. Cell. Oct. 5, 1990;63:167-174.
[cited by applicant]
Wrangle et al., Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 4(11):2067-2079 (2013) . . . .
[cited by applicant]
Wu, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990;46:801-801.
[cited by applicant]
Yeivin, et al. Sodium butyrate selectively induces transcription of promoters adjacent to the MoMSV viral enhancer. Gene. Jul. 15, 1992;116(2):159-64.
[cited by applicant]
Zeitlin, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. Jul. 2002;6(1):119-26.
[cited by applicant]
Zhang et al., Epigenetic manipulation restores functions of defective CD8
[cited by applicant]
Zhang, et al. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev. Jul. 2010;30(4):585-602.
[cited by applicant]
Zur Hausen, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970;228(5276):1056-1058.
[cited by applicant]
Arrighetti et al., Drug Combination with HDAC Inhibitors in Antitumor Therapy. Critical Reviews in Oncogenesis 20(1-2): 83-117 (2015).
[cited by applicant]
Petrich, et al. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leukemia and Lymphoma, 57(8):1755-1765 (Apr. 27, 2016).
[cited by applicant]
Chandrashekara, The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review. Indian Journal of Pharmacology 44(6): 665-671 (2012).
[cited by applicant]
Johnson et al., The Clinical Impact of Screening and other Experimental Tumor Studies. Cancer Treatment Reviews 2: 1-31 (1975).
[cited by applicant]
Kiany et al., Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment. Journal for Immunotherapy of Cancer 3(Supp. 2):P25 (2015).
[cited by applicant]
U.S. Appl. No. 16/317,750 Non-Final Office Action dated Jan. 11, 2021.
[cited by applicant]
Zhu et al., The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharmaceutical Research 32(3):779-792 (2015).
[cited by applicant]
U.S. Appl. No. 16/317,750 Non-Final Office Action dated Jul. 16, 2021.
[cited by applicant]
Banerji et al., A Phase I Pharmacokinetic and Pharmacodynamic Study Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research 18(9): 2687-2694 (2012).
[cited by applicant]
Bissonnette, R. et al., “Abstract B108: The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD- or PD-L1 blockage in the MC38 model of colon cancer”, Cancer Immunology Research, Nov. 2016, vol. 4, Issue 11, p…
[cited by applicant]
Kim, K. et al., “Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells”, PNAS, 2014, vol. 111, No. 32, pp. 11774-11779.
[cited by applicant]
U.S. Appl. No. 16/317,750 Final Office Action dated Oct. 29, 2021.
[cited by applicant]
International Application No. PCT/US17/42222 International Search Report and Written Opinion Mailed Sep. 29, 2017.
[cited by applicant]
U.S. Appl. No. 16/317,750 Non-Final Office Action dated May 27, 2022.
[cited by applicant]
Woods et al., Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade. Proceedings: AACR 106th Annual Meeting. Apr. 18, 2015, pp. 1-2; retrieved from https:…
[cited by applicant]
Feb. 22, 2022 Non-Final Office Action U.S. Appl. No. 16/961,200.
[cited by applicant]
Akimova, T. et al, “Histone/protein deacetylases and T-cell immune responses”, Blood, 2012, vol. 119, No. 11, pp. 2443-2451.
[cited by applicant]
ChemScene Safety Data Sheet for Nanatinostat (Year: 2022).
[cited by applicant]
Cherkassky, L. et al., “Human CAR T cells with cell-instrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition”, The Journal of Clinical Investigation, 2016, vol. 126, No. 8, pp. 3130-3144.
[cited by applicant]
Disis et al.: Use of tumour-responsive T cells as cancer treatment. Lancet. 373(9664):673-683 doi:10.1016/S0140-6736(09)60404-9 (2009).
[cited by applicant]
Eckschlager, T. et al., “Histone Deacetylase Inhibitors as Anticancer Drugs”, International Journal of Molecular Sciences, 2017, vol. 18, No. 1414, pp. 1-25.
[cited by applicant]
Jooeun et al., Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes are Enhanced by HDAC6 Inhibitor ACY241. Blood, American Society of Hematology 128(22): 2143 (2016).
[cited by applicant]
June, C. et al., “Engineering lymphocyte subsets: tools, trials and tribulations”, Nat Rev Immunol, 2009, vol. 9, No. 10, pp. 704-716.
[cited by applicant]
Kroesen, M. et al., HDAC inhibitors and immunotherapy; a double edged sword?, Oncotarget, 2014 vol. 5, No. 16, pp. 6558-6572.
[cited by applicant]
Li, Y. et al., “HDACs and HDAC Inhibitors in Cancer Development and Therapy”, Cold Spring Harbor Perspective in Medicine, 2016; 6; a02631, pp. 1-35.
[cited by applicant]
Mark, P.A. et al., “Histone Deacetylase Inhibitors: Potential in Cancer Therapy”, Journal of Cellular Biochemistry, 2009, vol. 107, pp. 600-608.
[cited by applicant]
Moffat, D. et al., “Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Ceacetylase Inhibitor”, Journal…
[cited by applicant]
PCT/US2019/013343 International Preliminary Report on Patentability dated Jul. 14, 2020.
[cited by applicant]
PCT/US2019/013343 International Search Report and Written Opinion dated Apr. 10, 2019.
[cited by applicant]